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ABSTRACT 23 
Endometriosis infiltrating the bowel can be treated medically in accurately selected women not 24 
seeking conception and without overt obstructive symptomatology. When the rectosigmoid junction 25 
is involved, the probabilities of intestinal symptoms relief, undergoing surgery after treatment 26 
failure, and developing bowel obstruction during hormonal treatment are around 70%, 10%, and 1-27 
2%, respectively. When the lesion infiltrates exclusively the mid-rectum, thus in cases of true 28 
rectovaginal endometriosis, the probabilities of intestinal symptoms relief and undergoing surgery 29 
are about 80% and 3%, respectively. Endometriotic obstructions of the rectal ampulla have not been 30 
reported. A recto-sigmoidoscopy or colonoscopy should be performed systematically before starting 31 
medical therapies, also to rule out malignant tumours arising from the intestinal mucosa. 32 
Progestogens are safe, generally effective, well tolerated, inexpensive, and should be considered as 33 
first-line medications for bowel endometriosis. Independently of symptom relief, intestinal lesions 34 
should be checked periodically to exclude nodule progression during hormonal treatment. 35 
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INTRODUCTION 42 
The bowel is the extragenital site most frequently affected by endometriosis [1,2]. It is estimated 43 
that 1 in 10 women with endometriosis harbours deep bowel lesions infiltrating not only the serosa 44 
and the sub-serosal tissue but also the muscular layer of the bowel wall. [2–4]. 45 
 Bowel endometriosis may cause functional, irritative-type symptoms (e.g., diarrhoea, 46 
intestinal cramping, hematochezia, passage of mucus) originating from the cyclic release of 47 
mediators of inflammation, and mechanical, obstructive-type symptoms (e.g., constipation and 48 
abdominal bloating), originating from enlarging nodules, intestinal angulation and strictures, and 49 
fibrotic tissue retraction. Moreover, some symptoms are associated with specific lesions (e.g., cyclic 50 
dyschezia and tenesmus are typical of rectal endometriosis) [5,6]. 51 
 In patients with severe sub-occlusive symptoms, there is no alternative to surgery. However, 52 
in many women, bowel endometriosis does not cause overt obstruction to faecal transit. Thus, when 53 
conception is not an issue, medical treatment might constitute a therapeutic alternative, especially 54 
considering that resection of endometriotic lesions with opening of the intestinal lumen may be 55 
followed by complications such as suture leakage, rectovaginal fistula formation, anastomosis 56 
stenosis, atonic bladder, and de novo bowel dysfunction [7–10]. The magnitude of the risk is 57 
associated also with the distance between the endometriotic lesion and the anal verge and with the 58 
coexistence of multiple lesions requiring more than one excision or segmental resection of a long 59 
intestinal tract [11–14]. Thus, identifying the exact location and anatomic characteristics of 60 
endometriotic bowel lesions appears important to correctly inform women’s decisions [3,15,16]. 61 
 The objectives of this narrative review are to define the pathological and endocrine basis 62 
underpinning the hormonal therapy of bowel endometriosis, synthesize the published evidence on 63 
the effect of available drugs in women with rectosigmoid and rectovaginal endometriosis 64 
separately, and propose a three-tiered risk stratification system to be used in patients not seeking 65 
conception and without frankly obstructive lesions.  66 
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 Ileocecal endometriosis and the rare, isolated nodules of the small bowel are not considered 67 
here because the high risk of intestinal obstruction associated with these types of lesions almost 68 
always mandates surgical resection [17,18]. 69 
 We aimed at retrieving reports of studies including patients with a definite diagnosis of 70 
endometriosis infiltrating the muscular layer of the mid-rectum (rectovaginal endometriosis), and of 71 
the proximal rectum and rectosigmoid junction (colorectal or rectosigmoid endometriosis). Only 72 
articles written in English and published in peer-reviewed journals in the last two decades were 73 
included. Case reports were considered separately with the specific intent of identifying additional 74 
patients who experienced occlusive events during medical treatment and that were not included in 75 
the considered studies. 76 
 77 
ANATOMICAL AND HISTOLOGICAL PREMISES 78 
 Probably due to local anatomical and physiological factors, endometriotic lesions of the left 79 
colon are much more frequent than those infiltrating the right colon [2]. Left lesions comprise those 80 
involving the rectosigmoid junction (proximal rectum plus distal sigmoid) and those above the 81 
rectosigmoid junction (nodules of the mid- and proximal sigmoid) [19,20]. Right infiltrating lesions 82 
generally involve the terminal ileum and the cecum. Endometriosis of the appendix is not 83 
considered in this review. Lesions infiltrating the mid-rectum, that is, below the rectosigmoid 84 
junction, are usually part of complex nodule or plaques of the deepest portion of the Douglas pouch, 85 
often infiltrating also the posterior vaginal fornix in addition to the anterior rectal wall [21]. 86 
Multiple lesions may coexist at different sites. With the exception of the terminal ileal loop, isolated 87 
small bowel nodules are very rare. 88 
 Endometriotic bowel lesions present three distinct histologic components, i) the usual 89 
ectopic endometrial-like mucosa; ii) smooth muscle fibres; iii) fibrous connective tissue [1]. The 90 
observation of a muscular component is not surprising whenever endometriosis infiltrates the wall 91 
of hollow viscera (e.g., bowel, bladder, ureter, vagina). The fibrotic component originates from 92 
Vercellini et al., 5 
tissue injury and remodelling induced by local inflammation associated with ectopic endometrium 93 
metabolic activity and, possibly, repeated micro-haemorrhages [22].  94 
 According to the retrograde menstruation theory, for endometriotic lesions to develop, 95 
particular anatomic conditions favouring endometrial cells shelter and implantation are needed. In 96 
the case of bowel endometriosis, this anatomical niche can be constituted by a physiologic intestinal 97 
flexure in close proximity with the salpinges, such as the rectosigmoid and ileocolic junctions 98 
[2,17], or by the juxtaposition of the anterior rectal wall and the posterior vaginal wall [21]. The 99 
final result of this pathological healing process is the formation of a sort of desmoplastic nodule. 100 
Intestinal plication around an endometriotic nodule is possible when an abundant mesocolon is 101 
present, and angulation and stricture may result as a consequence of scar retraction. In rectovaginal 102 
lesions, the coalescence of the anterior rectal and posterior vaginal walls leads to the formation of a 103 
fibrotic plaque that abolishes the distal portion of the Douglas pouch, usually without causing strict 104 
bowel angulation [21]. 105 
 106 
RATIONALE FOR HORMONAL TREATMENT OF BOWEL ENDOMETRIOSIS  107 
Progesterone receptors are expressed not only in the ectopic mucosa but also in the smooth muscle 108 
fibres of endometriotic nodules infiltrating the colon [23]. Accordingly, an effect should be 109 
expected on two out three components of these deep lesions. In addition, the anti-inflammatory 110 
properties of progestogens [24,25] might influence long-term fibrosis remodelling. However, a 111 
major impact of medical therapies on the often-predominant fibrotic component seems unlikely. 112 
Overall, nodules might undergo volume reduction over time, but fibrotic scarring, and thus 113 
angulation and stricture, may not subside. 114 
 More in general, two distinct therapeutic mechanisms can be hypothesized for the hormonal 115 
treatment of bowel endometriosis, one local, based on oestrogen and progesterone receptor 116 
expression of individual lesions, and one systemic, based on inhibition of the hypothalamic-117 
pituitary-ovarian axis. Defining the respective importance of the two mechanisms would be 118 
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relevant. In fact, it is currently assumed that a large part of endometriotic lesions might be 119 
refractory to the use of progestogens due to local progesterone resistance [26]. If this is true, 120 
theoretically progestogens should not be used to treat deep bowel endometriosis. However, if the 121 
systemic effect is more important, progestogens could be used not aiming at a direct local effect, 122 
but rather with the intent of preventing ovulation and menstruation, thus reducing the metabolic and 123 
proliferative activity of the ectopic mucosa through the induction of a stable hypo-oestrogenic 124 
milieu. This per se would abate the intra- and perilesional inflammation. In this case, suppression of 125 
the gonadal activity should attain partial lesion regression or temporary avoidance of progression 126 
independently of receptor status [27]. 127 
 Ferrero et al. [28] evaluated variation in rectovaginal endometriotic nodule volume in 128 
women treated with progestogens as monotherapy (n=44) or combined with letrozole (n=8), 129 
oestrogen-progestogen contraceptive pills (n=30), or triptorelin plus tibolone (n=10). At 130 
ultrasonography assessment, nodule volume decreased by about 20% after 6 months of therapy, and 131 
about 30% after 12 months, without significant differences between study drugs. Nodule volume 132 
decreased in 74% of the participants but increased by around 20% in 12% of them. 133 
 Egekvist et al. [29] followed 80 women with rectosigmoid or rectovaginal nodules treated 134 
for at least 12 months with a levonorgestrel-releasing intrauterine device (LNG-IUD; n=49), an oral 135 
contraceptive (n=12), a progestogen (n=9), or a combination of therapies (n=10). The nodule length 136 
and width increased in nine and six patients, respectively. During the study period, surgery was 137 
required in 6% of the patients. Of note, the LNG-IUD does not inhibit ovulation except for a few 138 
months after insertion [30], and acute rectosigmoid obstruction during LNG-IUD use has been 139 
described [31]. 140 
 Netter et al. [32] assessed rectosigmoid nodule measures variation in 43 women who 141 
underwent two MRIs at least 12 months apart. Nodule progression or regression was defined as, 142 
respectively, ³20% increase or ³20% decrease in length or in thickness. Any nodule with <20% 143 
variation was defined as stable. Stability, progression or regression was observed in 60%, 28%, and 144 
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12% of the women, respectively. Moreover, progression was detected in more than one-third of 145 
women who never experienced amenorrhoea, but in no patient who experienced continuous 146 
amenorrhoea during therapy with GnRH agonists, progestogens, or combined oral contraceptives. 147 
The risk of progression was inversely related to the length of periods of amenorrhoea.  148 
 Barra et al. [33] treated 83 women with symptomatic rectosigmoid nodules with oral 149 
dienogest, 2 mg/day. Mean nodule volume, as assessed at transvaginal ultrasonography, decreased 150 
by 7.5% after 6 months of progestogen therapy, and by 22.5% after 12 months. Endometriotic 151 
nodules regressed in 53% of the participants, remained stable in 35%, and progressed (an increase 152 
of ³10%) in 12%. 153 
 Nodule volume variation is not necessarily associated with symptom variation. As an 154 
example, Netter et al. [32] reported persistence of pain symptoms in the vast majority of women in 155 
whom the nodule regressed or remained stable. On the other hand, Egekvist et al. [29] observed that 156 
progression of nodule volume dimensions occurred without worsening of symptoms or health-157 
related quality of life. Barra et al. [33] also confirmed that the increase in endometriotic nodule 158 
volume during dienogest therapy was not always associated with worsening of clinical symptoms. 159 
 160 
ENDOMETRIOSIS OF THE MID-RECTUM (RECTOVAGINAL ENDOMETRIOSIS) 161 
A total of 1232 patients were included in 23 studies published in the period January 2000-May 2020 162 
(prospective cohort, n=11; patient preference trial, n=6; retrospective cohort, n=3; randomised 163 
controlled trial (RCT), n=2; before and after study, n=1; Table 1). The experimental study drug was 164 
a progestin in 11 studies, an oestrogen-progestogen combination (OPC) in 3, an aromatase inhibitor 165 
in 3, a GnRH agonist in 2, vaginal danazol in 2, an LNG-IUD in 1, and an etonogestrel-releasing 166 
implant in 1. The route of administration was mostly oral for progestogens and OPC, but also the 167 
vaginal, intramuscular, transdermal and intra-uterine route were assessed (Table 1). 168 
 The symptoms referred by recruited women were not always precisely described and 169 
accurately measured. Overall, the probability of partial or complete relief was 100% for rectal 170 
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tenesmus, feeling of incomplete evacuation and cyclic rectal bleeding, 92% for dyschezia, 64% for 171 
constipation, 58% for diarrhoea, 38% for passage of mucus, and 37% for abdominal bloating. In 172 
addition, dysmenorrhoea subsided in 78% of the considered women, deep dyspareunia in 77%, and 173 
non-cyclic pelvic pain in 73%. 174 
 A total of 38 women (3%) underwent surgery during the study period (persistence or 175 
worsening of pain symptoms, n=15; lesion size progression, n=3; indication not reported, n=20). No 176 
patient experienced bowel obstruction while using hormonal medications.  177 
 178 
ENDOMETRIOSIS OF THE PROXIMAL RECTUM AND DISTAL SIGMOID 179 
(RECTOSIGMOID JUNCTION ENDOMETRIOSIS) 180 
In the considered period, a total of 588 patients were included in 10 studies (prospective cohort, 181 
n=5; retrospective cohort, n=5; Table 2). However, 238 participants were enrolled in a single study 182 
[34]. The experimental study drug was a progestin in 3 studies, an OPC in 1, an aromatase inhibitor 183 
in 1, a GnRH agonist in 1, and multiple hormonal drugs in 4. The route of administration was 184 
always oral except for one study investigating the effect of a GnRH agonist injected intramuscularly 185 
in a depot formulation (Table 2). 186 
 Again, the description and assessment of symptoms sometimes were suboptimal. Overall, 187 
the probability of partial or complete relief was 100% for diarrhoea and passage of mucous, 98% 188 
for constipation, 90% for a feeling of incomplete evacuation and cyclic hematochezia, 82% for 189 
intestinal cramping, and 79% for abdominal bloating. In addition, dysmenorrhoea subsided in 80% 190 
of the considered women, deep dyspareunia in 78%, and non-cyclic pelvic pain in 67%. 191 
 A total of 123 women (21%) underwent surgery during the study period (persistence or 192 
worsening of pain symptoms, n=79; lesion size progression, n=26; intolerance of medical treatment, 193 
n=11; indication not reported, n=6; occlusive symptoms, n=1). Of note, 95 out of these 123 women 194 
were described in a single study [34]. Excluding this outlier, the probability of undergoing surgery 195 
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despite medical therapy was 8% (28/350; persistence or worsening of pain symptoms, n=11; 196 
intolerance of medical treatment, n=11; indication not reported, n=6). 197 
 198 
BOWEL OBSTRUCTION DURING MEDICAL TREATMENT 199 
Complete intestinal obstruction caused by endometriotic stricture is rare, as it is estimated to occur 200 
in < 1% of patients with bowel lesions [31,35]. However, for women considering medical treatment 201 
as an alternative to surgery, it would be important to know not only the general risk of such 202 
complication but the specific risk of this event while using suppressive therapies. In fact, the 203 
volume of 5%-10% of endometriotic intestinal nodules increases during pharmacological treatment. 204 
Only one case of sub-acute bowel obstruction in a woman with rectosigmoid junction endometriosis 205 
was described in the 33 studies considered in this review [34]. The type of medication used was not 206 
reported. 207 
 Among the case reports searched through PubMed, 15 additional cases of bowel obstruction 208 
during medical treatment use (isolated sigmoid colon endometriosis, n=3; rectosigmoid junction 209 
endometriosis, n=12) were identified. Ferrero et al. [36], Constantin et al. [37] and Millochau et al 210 
[38] observed sub-acute [36,38] or acute [37] intestinal obstruction caused by an endometriotic 211 
nodule infiltrating the sigmoid colon, in all cases after four years of cyclic [36,37] or continuous 212 
[38] treatment with a combined oral contraceptive.  213 
 Navajas-Laboa et al. [39] reported a case of endometriotic rectosigmoid junction obstruction 214 
occurred one month after discontinuation of an oral contraceptive used for more than 20 years. 215 
Scioscia et al. [40] briefly described seven women who underwent laparoscopic colorectal resection 216 
owing to progression of rectosigmoid stenosis after 9-16 months of daily oral therapy with 217 
desogestrel 75 µg (n=3), dienogest 2 mg (n=2), or nor-ethisterone acetate 2.5 mg (n=2). All nodules 218 
were larger than 4 cm. Whelton and Bhowmick reported a case of acute bowel obstruction due to 219 
stenosis of the rectosigmoid junction in a woman wearing an LNG-IUD as a treatment for severe 220 
deep endometriosis [31]. 221 
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 De Jong et al. described five patients who underwent emergency surgery because of an 222 
endometriotic stricture of the rectosigmoid junction. Three of these women used medical treatment, 223 
but it is unclear whether the bowel obstruction ensued during the use of respectively, a GnRH 224 
agonist, an LNG-IUD, and a progestogen, or if these drugs were used in the past for a limited time 225 
period. In fact, the authors only stated: “three patients were already treated with GnRH agonists or 226 
other hormone therapies” [35].  227 
 Of relevance, intestinal obstructions ensued during therapy for sigmoid or rectosigmoid 228 
lesions, but not for exclusively mid-rectal nodules. This supports the notion that the development of 229 
strict angulation of a bowel tract is a pre-requisite for occlusion to occur. An increase in 230 
endometriotic nodule dimension may further facilitate the process, as protrusion within a strictly 231 
angulated intestinal lumen may easily result in worsening of the stenosis to the point of impeding 232 
faecal transit. Importantly, for most of the reported cases, the baseline anatomic characteristics of 233 
bowel lesions were not described. Therefore, it is not possible to exclude that some of the women 234 
who experienced intestinal occlusion were not candidates to medical treatment according to 235 
currently agreed selection criteria.  236 
 237 
MEDICAL THERAPY FOR BOWEL ENDOMETRIOSIS: WHEN AND HOW.  238 
The quality of the available evidence on medical therapy for bowel endometriosis is suboptimal. 239 
Most studies were non-comparative. Several drugs were evaluated, often grouped in the same 240 
series, thus impeding definition of the effect of individual compounds and ascertainment of 241 
differences between therapies. Sometimes two different molecules were combined. Treatment 242 
periods were highly variable, ranging from a few months to years. It was not always possible to 243 
extract the precise location of bowel lesions, especially when the generic definition “colorectal 244 
endometriosis” was used. Thus, it may not be excluded that women at different prognosis were 245 
studied together, especially when patients with multiple lesions were included. Indeed, rectovaginal 246 
and recto-sigmoid junction lesions may coexist. Finally, when pain relief is considered, 247 
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discriminating the specific response to treatment of bowel endometriosis from that of other pelvic 248 
lesions seems difficult.  249 
 As a consequence, only general conclusions can be drawn from the assessment of published 250 
data. When the lesion is located above the mid-rectum, medical treatment should not be suggested if 251 
the degree of lumen stenosis is ³ 60%, or if the lesion infiltrates ³ 50% of the bowel circumference, 252 
or if the largest nodule diameter is >3 cm. In fact, the likelihood of substantial symptom 253 
improvement and definitive avoidance of surgery seems strictly related to the above lesion 254 
characteristics [3,4,41].   255 
 Moreover, medical therapy should never be suggested as an alternative to surgery for bowel 256 
endometriosis in patients with i) severe sub-occlusive intestinal symptoms, ii) ureteral stenosis with 257 
hydroureteronephrosis, iii) adnexal masses > 5 cm or with suspect ultrasonographic appearance, and 258 
iv) current pregnancy desire. Women wishing to conceive in the future should also be carefully 259 
counselled, not only because all the available hormonal medications interfere with ovulation, but 260 
also because bowel obstruction and perforation during pregnancy and ovarian stimulation have been 261 
reported [42–44]. In addition, intestinal procedures are more complex in the presence of a gravid 262 
uterus and are associated with risk of harms to both the mother and the foetus [45]. 263 
 In the absence of the above conditions, women should be informed in detail on the 264 
advantages and disadvantages of medical and surgical options. Patients should know that hormonal 265 
drugs might control, but not cure bowel endometriosis. Therefore, if medical treatment is chosen, 266 
this means using medications for years, possibly until the physiologic menopause. On the other 267 
hand, women should also know that excisional surgery as an isolated measure might not guarantee 268 
complete and/or long-lasting symptom relief. To reduce the risk of symptom and lesion recurrence, 269 
which is about 50% in 5 years [3,41,46,47], postoperative hormonal therapy may be needed anyway 270 
for an indefinite period of time. 271 
 Women desiring to avoid surgery, willing to use medications for years, who are 272 
psychologically tolerant of amenorrhoea and ready to deal with possible side effects of medications, 273 
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and without contraindications to available hormonal drugs, should then be informed about the 274 
absolute probability of i) experiencing pain and bowel symptoms relief, ii) undergoing surgery 275 
anyway for multiple reasons, iii) suffering episodes of frank bowel obstruction during medical 276 
treatment. This stage of the information process should be based on the precise location and 277 
characteristics of the lesion. In particular, patients should be aware that when the rectosigmoid 278 
junction is involved, the probability of intestinal symptoms relief is around 70%, and of undergoing 279 
surgery anyway around 10%. The risk of bowel obstruction is presumably between 1% and 2%. In 280 
most but not all cases, surgery can still be planned without the need for emergency procedures. 281 
 On the other hand, lesion dimension has little impact on the probability of success of 282 
medical therapy when the lesion infiltrates exclusively the mid-rectum as, to our knowledge, 283 
endometriotic obstructions of the rectal ampulla have not been reported. In case of true rectovaginal 284 
endometriosis, the probability of intestinal symptoms relief is around 80%, and that of undergoing 285 
surgery anyway for symptom persistence about 3%.  286 
 When multiple lesions are present, the shared decision process should focus on the lesion at 287 
worst prognosis. A recto-sigmoidoscopy or colonoscopy, in addition to transvaginal 288 
ultrasonography and MRI or other imaging techniques [15,16], should be suggested systematically 289 
before starting medical therapies, not only to verify the degree of lumen stenosis but also to rule out 290 
malignant tumours arising from the intestinal mucosa. 291 
 Women should also be aware that deciding between medical and surgical treatment is not 292 
necessarily an “either/or” decision but may be viewed as a stepwise approach. In a stepped care 293 
model, hormonal treatments should be tried first, resorting to surgery in women who do not respond 294 
to or do not tolerate medications [48]. However, when all the above selection criteria have been 295 
satisfied, generally no more than half of the patients with symptomatic bowel endometriosis 296 
actually remain available for a trial of medical therapy [20]. Obviously, the accurate selection of 297 
candidates for medical treatment on one hand reduces the number of potential users but, on the 298 
other hand, increases the likelihood of success and overall patient satisfaction with this choice. 299 
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 Most of the evidence on medical treatment for bowel endometriosis concerns the use of 300 
progestogens or OPC. These compounds are safe, generally effective, well-tolerated, inexpensive, 301 
and may be used for years. For these reasons, progestogens and continuous, low-dose OPC should 302 
be considered as first-line medications also for bowel endometriosis. A difference in the magnitude 303 
of the effect of these two drugs has not been demonstrated. Moreover, intestinal sub-acute 304 
obstruction has been reported during treatment with both, progestogens [31,35,40] and OPC [36–305 
39]. 306 
 However, the pathogenic premise behind medical treatment for deep endometriosis is 307 
different from that for ovarian endometriomas. In the latter case, the objective is inhibiting 308 
ovulation independently of the oestrogen content of the medication used, whereas when dealing 309 
with infiltrating lesions the objective is achieving the maximum possible disease quiescence to 310 
avoid lesion progression [30,48]. 311 
 Casper questioned the role of OPC in the management of endometriosis based on the 312 
hypothesis that owing to the supra-physiologic oestrogen content, these combinations may not 313 
adequately suppress lesions and relieve symptoms [24]. In addition, the results of a small RCT 314 
suggested a potentially detrimental role of even small amounts of a natural oestrogen [49]. The 315 
stimulating action of oestrogens on ectopic endometrium are generally effectively counteracted by 316 
progestogens when using OPC. Nevertheless, until this issue will be definitively disentangled, 317 
prescribing progestogen monotherapies to minimize the risk of lesion progression seems wiser 318 
when treating women with bowel endometriosis. Oral dienogest, 2 mg/day and nor-ethisterone 319 
acetate, 2.5 mg/day are similarly effective, although the former, costlier, compound seems better 320 
tolerated [50]. 321 
 Progestogens are usually associated with several side effects in a large proportion of users. 322 
However, in most cases, untoward effects are not severe enough to cause drug discontinuation. An 323 
exception is irregular bleeding, as it may cause pelvic pain and bowel symptoms worsening, is 324 
scarcely tolerated, and may limit treatment adherence [30,48]. Women must be informed in 325 
Vercellini et al., 14 
advanced that around one-third of women experiences repeated irregular bleeding and associated 326 
pelvic pain during progestogen treatment. Anticipating and describing these events may reduce 327 
anxiety, and providing information on tailored cycling may reduce the risk of drop out. 328 
Discontinuing progestogen assumption for one week generally allows successful management of 329 
breakthrough bleeding or prolonged spotting [30]. The frequency of these events generally 330 
decreases over time. Starting treatment with a GnRH agonist for a few months and then switching 331 
to an oral progestogen, may reduce the incidence of unexpected and painful bleeding episodes [51]. 332 
 Bowel lesions, especially when infiltrating the sigmoid colon and the rectosigmoid junction, 333 
should be checked periodically with imaging techniques [15,16], with the aim of identifying nodule 334 
progression during progestogen treatment despite partial or complete symptom relief [33]. 335 
Moreover, kidneys and ureters should also be checked regularly to rule out silent progressive 336 
hydroureteronephrosis, especially in women with large rectovaginal plaques extending laterally 337 
toward the pelvic sidewall [14]. 338 
 339 
A LESION-BASED, THREE-TIERED RISK STRATIFICATION SYSTEM FOR BOWEL 340 
ENDOMETRIOSIS 341 
The definition “bowel endometriosis” comprises different anatomical conditions associated with 342 
different clinical patterns. In particular, the likelihood of safely alleviating intestinal symptoms and 343 
avoiding surgery varies according to lesion location. 344 
 Bowel obstruction is probable when the lumen is intrinsically narrow, such as in cases of 345 
involvement of the last ileal loop and ileocecal valve [17,18]. Obstruction is possible when lesions 346 
infiltrate the wall of the sigmoid and the rectosigmoid junction, as the abundant mesocolon easily 347 
allows intestinal angulation around the nodule, which thus may act as a wedge impinging on a loop 348 
strictly fixed by fibrotic tissue. Conversely, the mid-rectum, which corresponds to the Douglas 349 
pouch, only has an anterior peritoneal covering. This, together with the large calibre and 350 
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distensibility of the rectal ampulla, renders sharp angulation and stenotic obstruction mechanically 351 
unlikely [14,20,48].  352 
 To define the therapeutic trade-offs that should inform patient choices, the potential harms 353 
of surgery for different bowel lesions should also be considered. Although lesion shaving is being 354 
fostered [8], actually nodulectomy (disk excision) and segmental resection are the procedures more 355 
frequently performed in case of bowel stenosis due to infiltrating endometriosis [3,4,10,13]. 356 
Proximal sigmoid nodule excision or segmental resection require standard surgically capabilities 357 
and are associated with a low risk of complications [9,12]. A temporary derivative ostomy is 358 
generally not necessary. Colorectal resection for rectosigmoid junction endometriosis may be 359 
technically demanding and is associated with a 5% risk of severe short- and medium-term 360 
complications [10,12]. The decision to confection an ostomy depends on local protocols, and 361 
variable percentages have been reported [4,12,13]. Patients requiring low-anterior rectal resection 362 
for rectovaginal endometriosis infiltrating the mid-rectum should be referred to centres of expertise 363 
where abdominal surgeons and gynaecologists specifically trained to manage complex pelvic 364 
endometriosis are available. The posterior vaginal fornix must be frequently excised at the same 365 
time, thus increasing the likelihood of rectovaginal fistula formation. For this reason, a protective 366 
ostomy is frequently performed. The risk of severe complication is around 10% [4,10,12,14,20]. 367 
 Based on these considerations, a three-tiered risk stratification system could be envisaged 368 
when managing bowel endometriosis. As endometriosis of the proximal sigmoid is associated with 369 
a moderate risk of obstruction, an indefinite likelihood of improvement during medical treatment, 370 
and a low risk of surgical complications, excision should be preferred.  371 
 Endometriosis of the rectosigmoid junction is also associated with a moderate risk of 372 
obstruction, but sufficient evidence exists to anticipate a fairly good effect of medical therapy. The 373 
risk of surgical complications is also moderate. In this sort of therapeutic equipoise, the value of the 374 
two treatment options appears similar. Pharmacological therapy could be tried first, resorting to 375 
surgery in case of inefficacy of or intolerance to medications. 376 
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 Rectovaginal endometriosis is not at risk of obstruction and usually responds well to 377 
hormonal compounds. Radical excision of this type of lesions carries a moderate-high risk of 378 
surgical complications [10,14]. Thus, medical treatment should be preferred. 379 
 Several other factors may influence the final decision, including the presence of multiple 380 
lesions, previous complex surgical procedures and overall surgical risk, age, and the long-term total 381 
expected costs of the different therapeutic options. In addition, the role of patients is here 382 
particularly important, as different women may be willing to accept different levels of surgical risks 383 
or may tolerate differently the same drug side effects. Whether to accept potential surgical 384 
morbidity or use medications for years is a very personal choice that should be based on complete, 385 
detailed, and unbiased information.  386 
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SUMMARY 387 
The quality of the evidence on medical therapy for bowel endometriosis is suboptimal and only 388 
general conclusions can be drawn. Medical treatment should not be suggested to women wishing to 389 
conceive, and also when severe sub-occlusive symptoms are present, the degree of lumen stenosis is 390 
³ 60%, or the lesion infiltrates ³ 50% of the bowel circumference, or the largest nodule diameter is 391 
>3 cm. Patients should be informed in detail about the advantages and disadvantages of medical and 392 
surgical options. Hormonal drugs might control, but not cure bowel endometriosis. This means 393 
using medications for long periods of time. However, excisional surgery as an isolated measure 394 
may not guarantee complete and/or long-lasting symptom relief, and postoperative hormonal 395 
therapy may be needed anyway. The information process should be based on the location and 396 
characteristics of the lesion. Approximately two-thirds of accurately selected patients with 397 
rectosigmoid endometriosis and three-fourths of those with rectovaginal lesions can be managed 398 
successfully with hormonal drugs. Progestogens are safe, effective, generally well-tolerated, 399 
inexpensive, may be used for years, and should be considered as first-line medications. Around one-400 
third of women experiences repeated irregular bleeding with associated pelvic pain during 401 
continuous progestogen treatment, and instructions should be provided on how to manage these 402 
events. The risk of obstruction during therapy is low in women with rectosigmoid junction 403 
endometriosis, and virtually absent in those with rectovaginal disease. However, bowel lesions 404 
should be checked periodically with imaging techniques to identify possible nodule progression 405 
during medical treatment despite symptom relief.  406 
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None. 409 
 410 
PRACTICE POINTS 411 
 412 
• Medical treatment is a valuable therapeutic option that could be proposed in selected women 413 
with bowel endometriosis. 414 
 415 
• About two-thirds of the patients with rectosigmoid endometriosis and three-fourths of those 416 
with rectovaginal lesions can be managed successfully with hormonal drugs, provided strict 417 
selection criteria are fulfilled. 418 
 419 
• Endometriotic bowel lesions should be checked periodically with imaging techniques to 420 
identify possible nodule progression during medical treatment despite symptom relief. 421 
 422 
RESEARCH AGENDA 423 
 424 
• Comparative effectiveness research on medical treatment versus surgery for endometriosis 425 
of the proximal rectum and rectosigmoid junction (colorectal endometriosis) 426 
 427 
• Comparative effectiveness research on medical treatment versus surgery for endometriosis 428 
of the mid-rectum (rectovaginal endometriosis) 429 
 430 
• GnRH agonists followed by progestogens to reduce breakthrough bleeding. 431 
  432 
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Table 1. Effect of aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRHa), oestrogen-progestins, and progestins as assessed in studies on the 
treatment of rectovaginal endometriosis (literature data, 2000-2020). 
 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Fedele et al., 2000 
[52]  
Prospective 15 Leuprolide acetate 3.75 
mg IM/28 day 
6 months NR Improvement of pain symptoms 
during treatment. High rate of pain 
recurrence after drug discontinuation. 
Transient regression of nodule size 
during treatment with return to 
baseline volume during follow-up. 
Fedele et al., 2001 
[53] 
Prospective 11 LNG-IUD 12 months Headache (37)          
Breast tenderness (37) 
Weight gain >1 kg (37)   
Seborrhoea, oily hair, 
acne (27) 
Significant improvement of dysm and 
CPP. Partial amelioration of deep 
dysp. Significant reduction of nodule 
size after 6 months of treatment. At 
the end of treatment period 9 patients 
were oligomenorrheic and 2 
experienced amenorrhea. 
Vercellini et al., 30 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Vercellini et al., 2005 
[54] 
RCT 90 Continuous low-dose 
monophasic OC (EE 0.01 
plus cyproterone acetate 3 
mg)/day (n = 45) 
 
(VS NETA 2.5 mg/day 
per os) (n = 45) 
12 months Group OC:           
Weight gain (16)         
Headache (7)   
Nausea (7)       
Depression (4)      
Decreased libido (4)                
Acne (2)          
Bloating (2)         
Breast tenderness (2)      
Hypertriglyceridemia (2)   
Group NETA:     
Weight gain (27)         
Decreased libido (9)                
Bloating (9)         
Depression (7)  
Headache (4)      
Acne (4)    
Similar pain relief and dropout rates. 
Higher satisfaction with treatment in 
NETA group. 
Vercellini et al., 31 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Erythematous cutaneous 
reaction  (2) 
Hefler et al., 2005 [55] Prospective 10 Vaginal anastrozole 0.25 
mg/day 
6 months No severe adverse events 
reported during study 
period 
Significant improvement of dysm and 
QoL. CPP and dysp remained 
unchanged during treatment. No 
significant changes in BMD and 
nodule volume size during treatment. 
Razzi et al., 2007 [56] Prospective 21 Vaginal danazol 200 
mg/day 
12 months Vaginal irritation (19) Significant improvement of dysm, 
dysp, and CPP. Significant reduction 
of nodule size after 6-months of 
treatment. No significant change of 
serum metabolic and thrombophilic 
parameters.  
Remorgida et al., 2007 
[57] 
Prospective 12 Letrozole 2.5 mg/day plus 
NETA 2.5/day per os 
6 months Weight gain (33)       
Mood swings (33)  
Weakness (25)            
Bone and joint pain (25)   
Significant pain relief and QoL 
improvement during treatment. At 6-
months’ follow-up recurrence of pain 
symptoms and worsening of QoL 
Vercellini et al., 32 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Vaginal spotting (17)  
Muscle aches (17)  
Headache (17)  
Depression (17)            
Hot flushes (8)        
Nausea (8)          
Decreased libido (8) 
scores in all patients. No BMD 
changes during treatment. 
Ferrero et al., 2009 
[58] 
PPT 82 Letrozole 2.5 mg plus 
NETA 2.5 mg/day per os  
(n = 41) 
 
(VS NETA 2.5 mg/day 
per os) (n = 41) 
6 months Group Letrozole plus 
NETA:             
Weight gain (20)             
Joint pain (17)  
Myalgia (12)   
Spotting (10)    
Breakthrough bleeding 
(5)   
Migraine (5)       
Myalgia (2)  
Greater pain relief with letrozole plus 
NETA, but fewer side effects and 
higher patient satisfaction rate with 
NETA only. Similar pain at follow-
up. No BMD changes during 
treatment. 
Vercellini et al., 33 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Depression (2)      
Hair loss (2)   
Decreased libido (2) 
Group NETA:     
Weight gain (17)        
Breakthrough bleeding 
(7)   
Spotting (7)     
Migraine (7)  
Depression (2)  
Vercellini et al., 2010  
[59] 
PPT 59a Vaginal ring (EE 15 µg 
plus etonogestrel 120 µg) 
(n = 38) 
 
(VS transdermal patch - 
EE 20 µg plus 
12 months Group vaginal ring:  
Bloating (10)          
Vaginal discomfort (7)              
Depression (6)        
Weight gain (6)  
Headache (6)    
Breast tenderness (5)           
Greater pain relief and satisfaction 
with vaginal ring. 
Vercellini et al., 34 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
norelgestromin 150 µg) (n 
= 21) 
Decreased libido (4)                     
Nausea (2)  
Group patch:          
Headache (18)       
Nausea (8)           
Breast tenderness (8)                  
Weight gain (5)      
Depression (5)     
Decreased libido (5)                 
Cutaneous reaction (5)                 
Bloating (3)         
Vaginal dryness (2)                    
Vomiting (2) 
Ferrero et al., 2011 
[60] 
Observational 
pilot study b 
15 Vaginal danazol 100 
mg/day  
6 months Seborrhea, oily hair, acne 
(27)                      
Headache (20)         
Significant improvement of dysm, 
dysp, CPP, and dyschezia and 
reduction of nodule size after 6 
months of treatment. High 
Vercellini et al., 35 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Weight gain >3 kg (13)   
Vaginal irritation (13) 
satisfaction rate with the treatment 
(80% of women were satisfied or 
very satisfied). 
Ferrero et al., 2011 
[61] 
RCT 35 Letrozole 2.5 mg plus 
NETA 2.5 mg/day per os   
(n = 17) 
 
(VS letrozole 2.5 mg/day 
per os plus  triptorelin 
11.25 mg/3 months IM) (n 
= 18) 
6 months NETA group:   
Weight gain (12)     
Decreased libido (12)               
Spotting (12)        
Myalgia and arthralgia 
(12)   
Depression (6) 
Triptorelin group:    
Myalgia and arthralgia 
(56)  
Decreased libido (22)           
Depression (22)    
Hot flushes (22)  
Vaginal dryness (17)          
Similar pain relief. Higher patient 
satisfaction with treatment in NETA 
group. Higher discontinuation rates 
in the triptorelin group. Greater 
nodule size reduction with triptorelin. 
Significant reduction of BMD in 
women treated with triptorelin.  
Vercellini et al., 36 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Insomnia (17)      
Hair loss (11)   
Headache (11)  
Weight gain (6)      
Mabrouk et al., 2012 
[62] 
Retrospective 106 Cyclic low-dose 
monophasic OC (EE 20 
μg plus drospirenone 3 
mg)/day (n = 75)  
 
(VS no treatment) (n = 31) 
5.8 (3.7) 
months c 
NR No significant variations in pain 
scores and nodule size in OC group. 
Significant worsening of dysm and 
deep dysp scores, and enlargement of 
nodule size in nonuser group. No 
significant changes in QoL scores 
during study period nor between 
groups.  
Vercellini et al., 2012 
[63] 
PPT 59a NETA 2.5 mg/day per os   
(n = 35) 
 
12 months Weight gain (34)  
Breakthrough bleeding 
(20)       
Decreased libido (19)                 
Vaginal dryness (12)                     
At the end of follow-up comparable 
satisfaction and improvement of deep 
dysp. 
Vercellini et al., 37 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
(VS second-line 
laparoscopic excision of 
endometriotic lesions) (n 
= 24) 
Spotting (11)             
Breast tenderness (6)                  
Bloating (5)           
Headache (4)           
Depression (4)        
Nausea (2)                
Leone Roberti 
Maggiore et al., 2014  
[64] 
PPT 143 DSG 75 µg/day per os (n 
= 60) 
 
(VS vaginal ring  - EE 15 
µg plus etonogestrel 120 
µg) (n = 83)             
12 months Group DSG:  
Breakthrough bleeding 
(8)    
Metrorrhagia (2)           
Weight gain (2) 
Group vaginal ring:                             
Weight gain (6)                
Spotting (2) 
Higher patient satisfaction with 
treatment in DSG group. Similar 
reduction in the volume of 
rectovaginal nodules. Comparable 
discontinuation rates.  
Morotti et al., 2014 
[65] 
PPT 144 DSG 75 µg/day per os (n 
= 62) 
 
6 months Group DSG:     
Bleeding (8)     
Higher satisfaction with treatment in 
DSG group. Similar pain relief (dysp 
Vercellini et al., 38 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
(VS cyclic low-dose 
monophasic OC - EE 20 
µg plus DSG 150 µg/day) 
(n  = 82) 
Weight gain (2)  
Mood changes (2)     
 
Group OC:       
Increased migraine (11)               
Bleeding (6)     
Weight gain (2)            
Mood changes (1)                
Decreased libido (1)                 
Acne (1)      
Peripheral edema (1) 
and CPP). Lower rate of migraine 
attacks with DSG. 
Morotti et al., 2014 
[66] 
Open-label 
prospective 
studyd 
25 DNG 2 mg/day per os (n = 
25) 
6 months Headache (16)          
Nausea (8)                
Breast tenderness (4) 
Improvement of pain symptoms, 
sexual function, QoL and satisfaction 
with DNG. 
Roman et al., 2015 
[67] 
Prospective 
case series 
70 Triptorelin acetate 11.25 
mg IM depot injection 
3.4 ± 1.8 
months 
-- Improvement of cyclic digestive 
complaints in more than half of 
patients. Constipation and non-cyclic 
Vercellini et al., 39 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
plus percutaneous 
estradiol 0.1% /day  
 
symptoms were improved in in less 
than a third of patients. 
Yela et al., 2015 [68] Prospective 16 DNG 2 mg/day per os 6 months Headache                  
Acne                  
Decreased libido       
Breast pain                  
Hair loss       
Nausea/vomit        
Bloating                
Vaginal dryness 
Significant improvement of pain 
symptoms (dysm, dysp, CPP, and 
dyschezia). No significant changes in 
volume size of endometriotic 
nodules. No significant changes in 
QoL and sexual function. 
Vercellini et al., 2016 
[50]  
Before-after 
study 
60a DNG 2 mg/day per os (n = 
29) 
 
(VS NETA 2.5 mg/day 
per os) (n = 31) 
6 months Group DNG:           
Weight gain (16)     
Spotting (13)        
Decreased libido (9)                
Vaginal dryness (7)                     
Bloating (6)              
Similar satisfaction with treatment 
and pain relief.  
Vercellini et al., 40 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Alopecia (5)         
Headache (3)          
Mood disorders (2)  
Breast tenderness (1)                       
Nausea (1)    
Breakthrough bleeding 
(1)  
              
Group NETA:    
Weight gain (31)     
Spotting (22)        
Decreased libido (14)                 
Vaginal dryness (13)                     
Mood disorders (8)  
Breast tenderness (8)                        
Bloating (5)          
Acne (4)            
Vercellini et al., 41 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Headache (3)           
Alopecia (1)        
Breakthrough bleeding 
(1)               
Leonardo-Pinto et al., 
2017 [69] 
Prospective 30 DNG 2 mg/day per os 12 months Headache (63)           
Breast pain (43)   
Decreased libido (43)  
Nausea/vomit (23) 
Significant improvement of pain 
symptoms (dysm, dysp, CPP, bowel 
pain) and QoL. No significant 
changes in volume size of 
endometriotic nodules. No relation 
between remission of pain symptoms 
and reduction of the volume of 
endometriotic nodules. 
Morotti et al., 2017 
[70] 
Retrospective 103 (61 
completed 
the 5 year 
follow-up) 
NETA 2.5 mg/day per os e 5 years Weight gain (30)     
Vaginal bleeding (23)  
Lipids alteration (12)  
Decreased libido (11)   
Significant improvement of dysm, 
CPP, dyschezia and dysp. At the end 
of study period 69% of women were 
satisfied or very satisfied with the 
treatment, 40.8% of all patients in the 
Vercellini et al., 42 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Headache (9)          
Bloating (8)       
Depression (7)            
Acne (5)        
Erythematous cutaneous 
reaction (1) 
intention to treat analysis (ITT). 
Significant reduction in the volume 
of the endometriotic nodules. At the 
end of study period, 11.9% of the 
patients displayed a volumetric 
increase of rectovaginal 
endometriosis. 
Scala et al., 2018 [71] Patient 
preference 
study 
100 (52 with 
rectovaginal 
endometriotic 
nodules) 
NETA (2.5 mg/day) 
 
(VS Extended-cycle OC – 
LNG 150 mcg and EE 30 
mcg for 84 days and EE 
10 mcg for 7 days) 
12 months Unscheduled bleeding 
Spotting 
 
No significant difference in the rate 
of satisfied patients at 12-month 
follow up between the two study 
groups. At 6-month and 12-month 
follow up, significant amelioration in 
the intensity of all pain symptoms 
compared with baseline in both 
groups. 
Significant within group reduction of 
rectovaginal endometriotic nodules 
Vercellini et al., 43 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
volumes, without between groups 
differences.  
Leonardo-Pinto et al., 
2018 [72] 
Prospective 30 DNG 2mg/die 12 months Headache (63) 
Decrease in desire (43) 
Nausea (23) 
Significant improvement of dysm, 
CPP and dysp. 
Significant improvement in sexual 
function (assessed with FSFI), but no 
significant enhancement in desire, 
lubrication and satisfaction domains 
of FSFI. Sexual function was not 
completely restored. 
Ferrero et al., 2019 
[73] 
Retrospective  44 Etonogestrel-releasing 
implant 
24 months Headache (23) 
Dizziness (14) 
Acne (7) 
Significant improvement of dysm, 
CPP, dyschezia and deep dysp. 
Significant improvement in all 
domains of the EHP-30 
Vercellini et al., 44 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
questionnaire. Significant reduction 
in endometriotic nodules volume. 
 
a Only the sub-group of patients with rectovaginal endometriosis was considered.                     
b Only patients with symptomatic rectovaginal endometriosis who had pain persistence after insertion of a LNG-IUD were selected. 
c Mean (SD). 
d Only patients with symptomatic rectovaginal endometriosis who had pain persistence and were unsatisfied after 6-months of treatment with NETA were selected.                                                                                                                                                                                                                                  
e In case of breakthrough bleeding the dose of NETA was increased from 2.5 to 5 mg/day. 
  
BMD = bone mineral density; CPP = chronic pelvic pain; DNG = dienogest; DSG = desogestrel; dysm = dysmenorrhoea; dysp = dyspareunia; EE = ethinyl estradiol; EHP = 
endometriosis health profile; FSFI = female sexual function index; IUD = intrauterine device; IM = intramuscular; LNG = levonorgestrel; NETA = nor-ethisterone acetate; 
NR = not reported; OC= oral contraceptive; PPT = patient-preference trial; QoL = quality of life; RCT = randomized controlled trial; VAS = visual analogue scale. 
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Table 2. Effect of aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRHa), oestrogen-progestogens, and progestogens as assessed in studies on 
the treatment of proximal rectum and rectosigmoid junction endometriosis (literature data, 2000–2020) a 
 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Ferrero et al., 2010 
[74] 
Prospective 
case series 
18 Triptorelin 11.25 mg/3 
months IM plus tibolone 
2.5 mg/day per os 
12 months  Hot flushes (33) 
Vaginal bleeding (33) 
Sweating episodes 3(17) 
Vaginal dryness and 
superficial dyspareunia 
(11) 
Nervousness and 
irritability (11) 
Weight gain (11) 
Sleeplessness (6) 
Fatigue (6) 
Difficulty in 
concentration (6) 
Significant improvement of pain 
symptoms. Improvement in intestinal 
function in patients with symptoms 
mimicking IBS-D. At 12-month 
assessment 13 (72%) women were 
very satisfied or satisfied, 2 (11%) 
were uncertain, and 3 (17%) were 
dissatisfied. 
Ferrero et al., 2010 
[75] 
Prospective 
case series 
40 NETA 2.5 mg/day per osb 12 months Worsening of constipation 
(7.5) 
Breakthrough bleeding (5)   
Significant improvement of dysm, 
dysp, CPP, dyschezia and diarrhea. 
No significant improvement in 
Vercellini et al., 46 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Weight gain (5) 
Spotting (2.5) 
Depression (2.5) 
Migraine attacks (2.5) 
 
patients with constipation, abdominal 
bloating and feeling of incomplete 
evacuation after bowel movements. 
60% of patients were satisfied or 
very satisfied with the treatment. 
Ferrero et al., 2010 
[76] 
Prospective 
case series 
6 Letrozole 2.5 mg/day plus 
NETA 2.5 mg/day per os 
6 months Breakthrough bleeding 
(17) 
Weight gain (17) 
Joint pain (17) 
Decreased libido (17) 
Significant improvement of dysm, 
dysp, CPP, and gastrointestinal 
symptoms. 
High satisfaction rate at the end of 
study period (67% of women were 
satisfied or very satisfied). 
No changes in BMD were identified. 
Harada et al., 2011 
[77] 
Retrospective 
case series 
4 DNG 2 mg/day per os 12 months Spotting (75)                          
Hot Flushes (50)          
Gastralgia (25)            
Depression (25) 
Significant improvement of pain 
symptoms and reduction in nodule 
size.  
Vercellini et al., 47 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Ferrari et al., 2012 
[78] 
Prospective 
case series 
26 Continuous low-dose 
monophasic OC (EE 15 μg 
plus gestodene 60 μg)/day     
12 months Breakthrough bleeding 
(38) 
Weight gain (23) 
Headache (12) 
Decreased libido (8)  
Significant improvement of dysm, 
dysp, CPP, and dyschezia.  
Significant reduction of nodule size 
after 12 months of treatment. 
High satisfaction rate at the end of 
study period (69% of women were 
satisfied or very satisfied). 
Vercellini et al., 2018 
[20] 
Retrospective 
cohort study 
50c Continuous low-dose 
monophasic OC (EE 15 μg 
plus gestodene 60 μg)/day;  
NETA 2.5 mg/day per os;  
DNG 2 mg/day per os 
40 (18-60) 
months 
Weight gain (32) 
Decreased libido (18) 
Bloating (16) 
Vaginal dryness (16) 
Headache (10) 
Mood changes (4) 
At final follow-up, 14 patients were 
very satisfied, 22 satisfied, 5 neither 
satisfied nor dissatisfied, 7 
dissatisfied, and 2 very dissatisfied. 
Significant improvements of bowel 
symptoms as assessed by both the 
Knowles-Eccersley-Scott-Symptom 
Questionnaire (KESS) and the 
numerical rating scale. 
Vercellini et al., 48 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Andres et al., 2019 
[34] 
Retrospective 
cohort study 
238 Oral progestogens, OCs, 
medroxyprogesterone 
acetate IM depot injection, 
LNG‐IUD, GnRH 
analogues 
 
 
6 months Complications in the 
clinical group: intestinal 
partial obstruction 
requiring urgent surgery 
(0.6). 
 
 
After 6 months, 60% patients 
reported improvement in pain 
symptoms, while 39.9% were 
referred for surgical treatment due to 
worsening or persistence of pain 
symptoms (28.6%), growth of 
endometriosis lesions (10.9%) or 
symptoms of bowel su-occlusion 
(0.4%). 
Significant reduction of dysm, dysp, 
CPP, dysuria and dyschezia in both 
medical and surgical treatment alike. 
Greater reduction in dyschezia and 
CPP in the medical group. 
Greater reduction of dyspareunia in 
the surgical group. Higher major 
Vercellini et al., 49 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
complications rates in the surgical 
group. 
Egekvist et al., 2019 
[29] 
Prospective 
study 
80 OCs, oral progestogens, 
LNG‐IUD, GnRH 
analogues with oestrogen-
progestogen add‐back 
12 months NR Significant improvement of 
dysmenorrhea. No significant 
improvement in CPP and dyschezia. 
Quality of life scores (SF-36 and 
EHP-30) were comparable to 
normative data for Danish women of 
similar age and did not change with 
time. No significant changes in 
volume of endometriotic nodules. No 
association between change in size of 
the rectosigmoid nodule and change 
in symptoms. 
Netter et al., 2019 [32] Retrospective 43 Continuous OCs, oral 
progestogens and GnRH 
analogues 
38.3 months 
(mean) 
NR About 60.5% of patients 
demonstrated stability of their 
colorectal lesions between the two 
Vercellini et al., 50 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
 
(VS no amenorrhoea or 
pregnancy) 
MRIs, 27.9% of patients ha a 
progression of lesions and 11.6% had 
a regression of lesions. Median 
duration of amenorrhoea was 
significantly lower in women with 
progression of lesions. Progression of 
rectosigmoid nodules was observed 
in 34% of patients without 
continuous amenorrhoea, in 39% 
who had never had amenorrhoea and 
in no patients with continuous 
amenorrhoea. 
Barra et al., 2020 [33] Retrospective  83 DNG 2mg/die 6 - 36 
months 
Weight gain (30)  
Abnormal uterine 
bleeding (27) 
Headache (21) 
Depression (10) 
Significant improvement of pain 
(dysm, dysp, CPP, dysuria and 
dyschezia) and intestinal symptoms. 
Progressive increase of the 
Endometriosis Health Profile-30 
Vercellini et al., 51 
Source Study design Patients 
enrolled (n) 
Study drug 
(comparator) 
Treatment 
period 
Adverse effects (%) Outcome 
Decreased libido (4) 
Acne (2) 
(EHP-30) and Gastrointestinal 
Quality of Life Index (GIQLI) scores 
was observed in the first two years of 
therapy. 
Significant reduction of 
endometriotic nodules volume. 
 
a Egekvist et al. [29] was not included because the exact number of patients who used different medical treatments (oral oestrogen-progestogens, progestogens, or LNG-IUD), 
the adverse effects associated with their use, and the precise pain symptoms or gastrointestinal symptoms variation could not be extracted from the published report.  
b In case of breakthrough bleeding the daily oral dose of NETA was doubled. 
c Only patients who chose medical treatment are here reported. 
 
BMD = bone mineral density; CPP = chronic pelvic pain; DNG = dienogest; dysm = dysmenorrhea; dysp = dyspareunia; EE = ethinyl-estradiol; GnRH = gonadotropin-
releasing hormone; IBS-D = diarrhoea-predominant irritable bowel syndrome; IM = intramuscular; IUD = intrauterine device; LNG = levonorgestrel; MRI = magnetic 
resonance imaging; NETA = nor-ethisterone acetate; NA = not applicable; NR = not reported; OC = oral contraceptive; SF-36 = Short Form 36. 
 
 
